The average one-year price target for Editas Medicine (NasdaqGS:EDIT) has been revised to $4.95 / share. This is an increase of 22.78% from the prior estimate of $4.03 dated November 14, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $1.01 to a high of $13.65 / share. The average price target represents an increase of 104.42% from the latest reported closing price of $2.42 / share.
What is the Fund Sentiment?
There are 328 funds or institutions reporting positions in Editas Medicine. This is an decrease of 3 owner(s) or 0.91% in the last quarter. Average portfolio weight of all funds dedicated to EDIT is 0.02%, an increase of 9.23%. Total shares owned by institutions increased in the last three months by 6.78% to 50,665K shares. 
The put/call ratio of EDIT is 0.09, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,592K shares representing 2.66% ownership of the company. No change in the last quarter.
IWM - iShares Russell 2000 ETF holds 2,117K shares representing 2.17% ownership of the company. In its prior filing, the firm reported owning 2,213K shares , representing a decrease of 4.56%. The firm increased its portfolio allocation in EDIT by 83.13% over the last quarter.
Nuveen holds 2,092K shares representing 2.14% ownership of the company. In its prior filing, the firm reported owning 950K shares , representing an increase of 54.59%. The firm increased its portfolio allocation in EDIT by 98.40% over the last quarter.
Geode Capital Management holds 2,040K shares representing 2.09% ownership of the company. In its prior filing, the firm reported owning 1,964K shares , representing an increase of 3.72%. The firm decreased its portfolio allocation in EDIT by 20.80% over the last quarter.
VSEQX - Vanguard Strategic Equity Fund Investor Shares holds 1,872K shares representing 1.92% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
